ATE362483T1 - Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen - Google Patents

Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen

Info

Publication number
ATE362483T1
ATE362483T1 AT02700240T AT02700240T ATE362483T1 AT E362483 T1 ATE362483 T1 AT E362483T1 AT 02700240 T AT02700240 T AT 02700240T AT 02700240 T AT02700240 T AT 02700240T AT E362483 T1 ATE362483 T1 AT E362483T1
Authority
AT
Austria
Prior art keywords
expressing cells
receptor
targeting molecules
universal carrier
cys
Prior art date
Application number
AT02700240T
Other languages
English (en)
Inventor
Ludger Johannes
Eric Tartour
Bruno Goud
Wolf Fridman
Original Assignee
Inst Curie
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Paris Curie filed Critical Inst Curie
Application granted granted Critical
Publication of ATE362483T1 publication Critical patent/ATE362483T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02700240T 2001-02-01 2002-02-01 Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen ATE362483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01400255A EP1229045A1 (de) 2001-02-01 2001-02-01 Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen

Publications (1)

Publication Number Publication Date
ATE362483T1 true ATE362483T1 (de) 2007-06-15

Family

ID=8182611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700240T ATE362483T1 (de) 2001-02-01 2002-02-01 Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen

Country Status (11)

Country Link
US (3) US7632514B2 (de)
EP (2) EP1229045A1 (de)
JP (1) JP4296536B2 (de)
AT (1) ATE362483T1 (de)
CA (1) CA2435712C (de)
CY (1) CY1106789T1 (de)
DE (1) DE60220136T2 (de)
DK (1) DK1355928T3 (de)
ES (1) ES2287239T3 (de)
PT (1) PT1355928E (de)
WO (1) WO2002060937A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (de) * 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
ATE292144T1 (de) 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1938836A1 (de) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Verbindungen mit Shigatoxin-B-Untereinheit und Mittel zur Stimulation von NKT-Zellen
GB0724360D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
US20090214438A1 (en) * 2007-12-18 2009-08-27 Institut Curie Methods and compositions for the preparation and use of toxin conjugates
EP2072060A1 (de) * 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten
EP2548571A1 (de) 2011-07-22 2013-01-23 Institut Curie Zusammensetzungen mit Mitteln zum Targeting von mindestens einem Antigen zu dendritischen Zellen
EP2740493A1 (de) 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin für Antikrebstherapien
EP2740491A1 (de) * 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin zur Verwendung als Kontrastmittel zur Bildgebung und Therapie
EP3058956A1 (de) 2015-02-23 2016-08-24 Institut Curie Kombinierte Impfungs-/Strahlentherapie zur Krebsbehandlung
EP3612552A1 (de) * 2017-04-20 2020-02-26 Institut National de la Santé Et de la Recherche Médicale Peptide, insbesondere polypeptide, phagenanzeige-screening-verfahren und assoziierte mittel und deren verwendungen für forschungs- und biomedizinanwendungen
US12527854B2 (en) 2019-06-04 2026-01-20 Institut Curie Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof
WO2022117764A1 (en) * 2020-12-02 2022-06-09 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
CN113754733B (zh) * 2021-09-18 2023-10-20 上海交通大学 一种vGPCR蛋白靶向肽的筛选方法及其嵌合毒素与应用
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0725838A4 (de) * 1993-10-26 1997-02-26 United Biomedical Inc Strukturierte synthetische antigenbanken als diagnostika, impfstoffe und therapeutische mittel
DE4430601A1 (de) * 1994-08-22 1996-02-29 Beiersdorf Ag Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander
CA2218601A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
FR2766193B1 (fr) * 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1229045A1 (de) 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
ATE292144T1 (de) * 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
US20090035330A1 (en) * 2005-05-19 2009-02-05 Marianne Dewerchin Vaccine Composition Comprising B-Subunit Of E. coli Heat Toxin And An Antigen And An Adjuvant
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
EP1991565B1 (de) * 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Chimäre Shigatoxoidproteine
AU2007240614B2 (en) * 2006-04-20 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on Shiga toxin type 1 protein
EP2517723B1 (de) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
EP1938836A1 (de) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Verbindungen mit Shigatoxin-B-Untereinheit und Mittel zur Stimulation von NKT-Zellen
JP4954293B2 (ja) * 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
EP2145873A1 (de) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Neue Verbindungen, die eine Schutzaktivität gegen die Wirkung von Toxinen und Viren über einen intrazellulären Wirkungsmechanismus entfalten
US8969529B2 (en) * 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
RU2626949C2 (ru) 2011-10-14 2017-08-02 ЗДиТиЭл, ИНК. Защитный элемент или документ с защитным признаком с по меньшей мере одним признаком динамического эффекта

Also Published As

Publication number Publication date
US7632514B2 (en) 2009-12-15
US20150045536A1 (en) 2015-02-12
DK1355928T3 (da) 2007-09-24
DE60220136D1 (de) 2007-06-28
EP1229045A1 (de) 2002-08-07
US8852612B2 (en) 2014-10-07
US20040110935A1 (en) 2004-06-10
EP1355928B1 (de) 2007-05-16
US9603923B2 (en) 2017-03-28
JP2004531230A (ja) 2004-10-14
EP1355928A1 (de) 2003-10-29
CA2435712A1 (en) 2002-08-08
JP4296536B2 (ja) 2009-07-15
DE60220136T2 (de) 2008-01-24
ES2287239T3 (es) 2007-12-16
CY1106789T1 (el) 2012-05-23
WO2002060937A1 (en) 2002-08-08
US20100196418A1 (en) 2010-08-05
CA2435712C (en) 2012-07-10
PT1355928E (pt) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60220136D1 (de) Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
BR0211926A (pt) agentes para realçar a resposta imune
EP1025217A4 (de) Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DK1360203T3 (da) Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
EP1423510A4 (de) Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
EA200000144A1 (ru) Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
ATE421584T1 (de) Cpg rezeptor (cpg-r) und darauf bezogene methoden
ATE468533T1 (de) Enzym-protein-komplex
WO2003107009A3 (en) Methods for improving a binding characteristic of a molecule
ATE246516T1 (de) Neue enzyme und prodrugs für adept
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
DE69814735D1 (de) Carbazolcarboxamide als 5-HT1F Agonisten
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
DE60203491D1 (de) Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
FR2797689B1 (fr) Utilisation de composes synthetiques pour des immunodosages
EP1293567A4 (de) Gpr8 ligand und dafuer kodierende dna(02.01.02)
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355928

Country of ref document: EP